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Risk factors for recurrent Clostridium difficile
infection (CDI) hospitalization among hospitalized
patients with an initial CDI episode: a retrospective
cohort study
Marya D Zilberberg1,2*, Kimberly Reske3, Margaret Olsen3, Yan Yan3 and Erik R Dubberke3
Abstract
Background: Recurrent Clostridium difficile infection (rCDI) is observed in up to 25% of patients with an initial CDI
episode (iCDI). We assessed risk factors for rCDI among patients hospitalized with iCDI.
Methods: We performed a retrospective cohort study at Barnes-Jewish Hospital from 1/1/03 to 12/31/09. iCDI was
defined as a positive toxin assay for C. difficile with no CDI in previous 60 days, and rCDI as a repeat positive toxin
≤42 days of stopping iCDI treatment. Three demographic, 13 chronic and 12 acute disease characteristics, and 21
processes of care were assessed for association with rCDI. Cox modeling identified independent risk factors for rCDI.
Results: 425 (10.1%) of 4,200 patients enrolled developed rCDI. Of the eight risk factors for rCDI on multivariate
analyses, the strongest three were 1) high-risk antimicrobials following completion of iCDI treatment (HR 2.95, 95%
CI 2.25-3.86), 2) community-onset healthcare-associated iCDI (HR 1.80, 95% CI 1.41-2.29) and 3) fluoroquinolones
after completion of iCDI treatment (HR 1.56, 95% CI 1.63-2.08). Other risk factors included gastric acid suppression,
≥2 hospitalizations within prior 60 days, age, and IV vancomycin after iCDI treatment ended.
Conclusions: The rCDI rate was 10.1%. Recognizing such modifiable risk factors as certain antimicrobial treatments
and gastric acid suppression may help optimize prevention efforts.
Keywords: C. difficile, Risk factors, Recurrence
Background
Over the past decade Clostridium difficile infection (CDI)
has increased in both frequency and severity in the US
and abroad. A study from Quebec identified a 5-fold rise
in the incidence of hospitalizations with CDI over 13 years,
accompanied by a doubling in the risk of complicated dis-
ease [1]. Similarly, multiple US-based studies have re-
ported a more-than-doubling of hospitalizations with a
CDI diagnosis between 2000 and 2005 [2,3]. These num-
bers have continued to rise through 2009, albeit less rap-
idly [4]. Much of this growth is thought to be due to the
recent emergence of the hypervirulent epidemic strain of
C. difficile, BI/NAP1/027. A fluoroquinolone-resistant
toxin overproducer, this strain has now been detected in
most of the states in the US, in North America, Europe
and beyond [5].
One of the most challenging aspects of CDI is its pro-
pensity to recur. Both metronidazole and vancomycin,
first-line therapies recommended in the joint evidence-
based practice guideline from the Society of Healthcare
Epidemiology of America (SHEA) and Infectious Dis-
eases Society of America (IDSA), have exhibited un-
acceptably high rates of recurrence [6]. Indeed, a recent
meta-analysis has found that CDI recurs in 13% – 50%
of all patients after an initial episode, and in the setting
of a randomized controlled trial, the recurrence rate was
25% [7-9].
Recurrent CDI (rCDI) is a cause of much morbidity,
and its economic impact is likely substantial. Several
studies have identified important risk factors for rCDI,
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including advanced age, chronic renal insufficiency, ele-
vated white blood cell count, low serum albumin, use of
proton pump inhibitors (PPI), and continued use of
systemic antimicrobials during the initial CDI episode
(iCDI) [7,10-13]. However, a meta-analysis identified
major gaps in our understanding of the risk factors for
CDI recurrence [7]. Although the authors found con-
comitant antimicrobials, gastric acid suppressants and
older age to be strongly predictive of rCDI, other factors,
including iCDI treatment and specific non-CDI antimi-
crobials, could not be evaluated adequately due to the
lack of robust data. Additionally, most studies have
focused on the factors immediately preceding rCDI on-
set, ignoring the possibility that factors present at or
near the onset of the iCDI episode may also impact this
risk. In fact, recent data suggest that the burden of
community-onset healthcare-facility associated (CO-
HCFA) CDI is much higher than previously appreciated,
and poses an additional risk pool for inpatient exposure
[14,15]. Since CO-HCFA implies an ongoing exposure to
the healthcare system, it may itself be a marker for a
recurrence.
A precise understanding of who is likely to recur is an
important clinical question for two reasons. First, if
there are modifiable exposures that increase this risk,
knowing what they are may aid clinicians in avoiding
them. Second, if patient characteristics not subject to
modification predispose to rCDI, recognizing them may
help target preventive measures more effectively. In
order to define more fully the risk factors for rCDI, we
conducted a single center retrospective cohort analysis
among patients hospitalized with an iCDI episode.
Methods
This study was approved by the Washington University
Institutional Review Board, and its conduct was in com-
pliance with the Helsinki Declaration.
Cohort definition
We conducted a retrospective cohort study of all adult
(age ≥18 years) patients with an inpatient episode of
iCDI at Barnes-Jewish Hospital (BJH) between January 1,
2003, and December 31, 2009. An episode of CDI was
defined as a positive toxin assay (C. DIFFICILE TOX
A/B II from Techlab, Blacksburg, VA, USA) for C. difficile.
Because the hospital laboratory performs a test for C.
difficile only if the treating physician suspects CDI and
if the stool is unformed, all patients with positive toxin
results were considered to be CDI case patients. The
first episode of CDI during the study period in the ab-
sence of any CDI in the prior 60 days was defined as
the iCDI, and patients were included only once. Pa-
tients were excluded if they died during or were dis-
charged to hospice from the iCDI hospitalization.
All included patients were followed for 42 days from
the date of the end of iCDI treatment or until rCDI on-
set, defined as a repeat positive toxin within this time
frame. Initial CDI cases were categorized according to
published surveillance definitions as community-onset
healthcare facility-associated (CO-HCFA) (indetermin-
ate CDI cases were grouped with CO-HCFA), health-
care facility-onset (HCFO), and community-associated
(CA) [16].
Data sources
Demographic and clinical data were derived from BJH
Medical Informatics databases and the BJH electronic
medical records. The data available from the Informatics
databases included C. difficile toxin assay results and
date of stool collection; patient demographics; dates
of admission and discharge; discharge disposition; ad-
mission location; ICD-9-CM diagnosis (used to define
underlying comorbidities in the year prior and during
the index hospitalization) and procedure (assessed only
during the index hospitalization) codes; dates of ICU
stays; start and stop dates of all inpatient CDI treat-
ments, gastric acid suppressors and antimicrobials; and
white blood cell count, hemoglobin, serum creatinine,
and serum albumin levels on admission and at the time
of positive C. difficile toxin assays from the index admis-
sion and all readmissions in the 42 days after iCDI treat-
ment end. The BJH medical records included data on
antimicrobials and CDI treatments the patient received
as an outpatient within the BJH system, and whether a
readmission was for CDI. In addition, admission and
discharge summaries were reviewed for all included hos-
pitalizations to help determine whether the patient had
a history of CDI at another healthcare facility or as
an outpatient.
Statistical analyses
The exposure interval was divided into three periods: 1)
from hospital admission until diagnosis of iCDI, 2) from
the time of diagnosis of iCDI until the end of its treat-
ment, and 3) from the end of iCDI treatment until the
onset of recurrence or until the end of the 42-day moni-
toring period for recurrence. We compared patients with
rCDI to those without rCDI based on their characteristics
in these time periods. Cox proportional hazards modeling
was used to determine variables associated with at least
one episode of rCDI on univariate analysis. Antimicrobials
were categorized based on association with CDI as high-
risk (cephalosporins, aminopenicillins, and clindamycin),
low-risk (aminoglycosides, beta lactamase inhibitors, car-
bepenems, daptomycin, doxycycline, linezolid, macrolides,
rifampin, rifaximin, and tigecycline), fluoroquinolones
(>90% was ciprofloxacin), and intravenous vancomycin
[17,18]. Gastric acid suppressors (histamine receptor 2
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blockers [HR2B] and proton pump inhibitors [PPI]),
choice and duration of iCDI treatment, and iCDI severity,
as defined by the SHEA/IDSA Clinical Practice Guidelines
for CDI, were also assessed as potential risk factors for
rCDI [6].
We employed extended Cox proportional hazards
modeling to determine independent risk factors for at
least one episode of rCDI, with variable selection accord-
ing to the methodology of Hosmer-Lemeshow [19]. Vari-
ables eligible for inclusion in the multivariable models
were those associated with increased risk of rCDI from
the literature or those with clinical or biologic plausibil-
ity, and those with p-values <0.20 in the univariate ana-
lyses. Antimicrobial exposures from the end of CDI
treatment until rCDI or 42 days were analyzed as time-
dependent variables. Backward stepwise selection was
used to arrive at the best-fitting and most parsimonious
model. All relevant 2-way interactions were tested after
selection of the main effects, and included in the final
models only if they were significant at the alpha ≤0.05.
The proportional hazards assumption was verified by
assessing the parallel nature of curves in log-log plots.
The appropriate functional formats of continuous vari-
ables were determined by examining nonparametric re-
gression (smoothing) plots with a restricted cubic spline
function. To facilitate interpretation of results, the haz-
ard ratios for the piecewise linear spline variable (fluoro-
quinolone exposure while on CDI treatment) compared
the hazards of developing CDI for values between the
75th and the 25th percentiles of the variable [20]. To as-
sess the importance of time dependency for antimicro-
bial exposures that occur after CDI treatment, these
exposures included in the final model were also analyzed
in a time-independent fashion.
All analyses were performed in SAS version 9.3 (SAS
Institute, Cary, NC) and R (R Foundation, Vienna,
Austria) [21]. All statistical testing was two-tailed with
significance set at the alpha level ≤ 0.05.
Results
Among the 4,200 patients enrolled with iCDI, 425 (10.1%)
had at least one rCDI identified. Those with a recurrence
were older (median age 64.8, range 18.3 – 98.2, vs. 61.6,
range 18.0 – 102.4), and had a greater comorbidity bur-
den, as evidenced by the higher Charlson score than those
without (Table 1). Of the specific comorbidities, diabetes
mellitus was more prevalent in the rCDI group than in
the group without rCDI. Notably, prior exposure to the
healthcare system was more likely among those with rCDI
than those without. Persons with rCDI were nearly twice
as likely to fit the surveillance definition for CO-HCFA
CDI during their initial episode (39%) as those without
rCDI (22%, p < 0.001). Consistent with this, patients with
rCDI had a higher frequency of at least one inpatient
admission within 60 days prior to the iCDI episode (53%
vs. 39%, p < 0.001), as well as a higher risk for multiple re-
cent hospitalizations than those without rCDI (Table 1).
The iCDI admission laboratory data did not differ sub-
stantively between the groups.
There were several differences between patients with
and those without rCDI with respect to exposure to
medications known to raise the risk of CDI (Table 2).
Nearly ¾ of all patients in each group were on at least
one antimicrobial at the onset of their iCDI. There were
no differences in antibiotics considered to be “high-risk”
for causing CDI between the rCDI and non-rCDI
groups. Conversely, antimicrobials designated as “low-
risk” for CDI were used with lower frequency in patients
with (22%) compared to those without rCDI (28%,
p = 0.02). Fluoroquinolone treatment was more prevalent
during the iCDI onset among those with rCDI (28%)
than those without (23%, p = 0.02). Furthermore, pa-
tients with rCDI who used gastric acid suppressors were
nearly twice as likely as those without to be started on
one within 24 hours of the iCDI diagnosis (Table 2).
Although there were no differences in the treatment regi-
men aimed at the iCDI episode, patients who developed
rCDI were more frequently started on such high-risk medi-
cations as gastric suppressors and non-CDI antimicrobials,
regardless of their designation as high- or low-risk, after
the onset of iCDI (Table 2). Those with subsequent rCDI
were more likely to be discharged to a healthcare facility
following the iCDI hospitalization than those without
rCDI, though this difference did not reach statistical signifi-
cance. Following the hospitalization with iCDI, patients
with a subsequent rCDI were also more likely to be re-
admitted to the hospital both before and/or after the end
of the iCDI treatment (Table 3).
In a multivariate Cox proportional hazards model,
where we examined 49 potential covariates for their im-
pact on the risk of rCDI, eight factors emerged as pre-
dictive of a future episode of rCDI (Table 4). In addition
to age, case status of iCDI designation of CO-HCFA was
strongly associated with rCDI, increasing its risk by 80%
(HR 1.80, 95% CI 1.41 to 2.29). In a similar vein, having
had two or more inpatient hospitalization within 60 days
prior to the onset of CDI was associated with an in-
creased risk of rCDI (HR 1.40, 95% CI 1.04-1.89). A
number of modifiable risk factors also predicted the risk
of rCDI. They included initiation of gastric acid suppres-
sors at the time of iCDI diagnosis (HR 1.36, 95% CI
1.004 to 1.85), and cumulative exposure to fluoroquino-
lones while on iCDI therapy (HR 1.45, 95% CI 1.09 to
1.41). Exposure to fluoroquinolones (HR 1.56, 95% CI
1.16 to 2.08), IV vancomycin (HR 1.45, 95% CI 1.09 to
1.92), and high-risk antimicrobials (HR 2.95, 95% CI
2.25 to 3.86) at any time t after the end of iCDI therapy
ended also increased the risk of rCDI. Demonstrating
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Table 1 Patient characteristics and treatments at hospital admission involving the initial CDI episode
Patient characteristics
Patients who developed rCDI Patients who did not develop rCDI Hazard ratio
(n = 425) (n = 3775) 95% CI
Demographics
Age, years (median[range]) 64.8 (18.3 – 98.2) 61.6 (18.0 –102.4) 1.01 (1.01 – 1.02)
Gender: female 210 (49) 1824 (48) 1.05 (0.87 – 1.27)
Comorbiditiesa
Myocardial infarction 40 (9) 328 (9) 1.12 (0.81 – 1.55)
Congestive heart failure 108 (25) 854 (23) 1.23 (0.99 – 1.53)
Peripheral vascular disease 34 (8) 269 (7) 1.13 (0.79 – 1.60)
Cerebrovascular disease 41 (10) 256 (7) 1.51 (1.10 – 2.09)
Chronic renal failure 21 (5) 190 (5) 0.98 (0.64 – 1.53)
Dementia 5 (1) 23 (1) 1.83 (0.76 – 4.41)
Chronic obstructive pulmonary disease 116 (27) 912 (24) 1.18 (0.95 – 1.46)
Rheumatologic disease 18 (4) 146 (4) 1.11 (0.69 – 1.78)
Peptic ulcer disease 20 (5) 154 (4) 1.18 (0.75 – 1.85)
Mild liver disease 17 (4) 201 (5) 0.81 (0.50 – 1.32)
Moderate to severe liver disease 12 (3) 134 (4) 0.86 (0.48 – 1.53)
Diabetes 135 (32) 975 (26) 1.32 (1.08 – 1.62)
Paraplegia or hemiplegia 12 (3) 78 (2) 1.40 (0.79 – 2.45)
Any malignancy (excluding leukemia/lymphoma) 83 (20) 770 (20) 0.99 (0.78 – 1.25)
Leukemia or lymphoma 78 (18) 660 (18) 1.05 (0.82 – 1.34)
Metastatic solid tumor 56 (13) 449 (12) 1.19 (0.90 – 1.58)
HIV/AIDS 10 (2) 66 (2) 1.30 (0.70 – 2.44)
Charlson composite score
0-2 223 (53) 2182 (58) Ref
3-5 117 (28) 922 (24) 1.27 (1.01 – 1.59)
> = 6 85(20) 671 (18) 1.32 (1.03 – 1.69)
Case statusb
HCFO/HCFA 203 (48) 2332 (62) Ref
CA or unknown 57 (13) 597 (16) 1.07 (0.79 – 1.43)
CO/HCFA, indeterminate, or non- BJH HCFA 165 (39) 846 (22) 2.17 (1.76 – 2.66)
Admitted from another healthcare facility 109 (26) 1019 (27) 0.97 (0.78 – 1.21)
Number of inpatient admissions in previous 60 days
0 200 (47) 2313 (61) Ref
1 150 (35) 1021 (27) 1.70 (1.37 – 2.10)
2+ 75 (18) 441 (12) 1.96 (1.50 – 2.55)
Baseline laboratory datac
Low albumin at admission 52 (12) 522 (14) 0.94 (0.70 – 1.25)
Low WBC at admission 44 (10) 420 (11) 0.92 (0.68 – 1.26)
High WBC at admission 236 (56) 2122 (56) 0.86 (0.66 – 1.12)
Low hemoglobin at admission 182 (43) 1572 (42) 1.09 (0.90 – 1.32)
High creatinine at admission 108 (25) 947 (25) 1.04 (0.84 – 1.30)
Low creatinine clearance 218 (51) 1636 (43) 1.43 (1.18 – 1.73)
rCDI = recurrent C. difficile infection.
aComorbidities diagnosed within previous 1 year (identified by ICD-9-CM diagnosis codes.
bHCFO = health care facility onset; HCFA = healthcare facility-associated; CA = community acquired; CO = community onset. Case she status for 6 patients’ was
unknown: 1 among those who developed rCDI and 5 among those who did not.
cThe following threshold values defined “high” and “low” levels: albumin <2.5 g/dL; WBC low <3.8*103/mm3; WBC high >9.8*103/mm3; hemoglobin <10.0 g/dL;
creatinine >1.5 ug/dL; creatinine clearance <70 mL/min. WBC = white blood cells.
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the importance of time dependency of concomitant anti-
microbials started after CDI treatment ended, when
post-CDI treatment antimicrobials were modeled in a
time independent fashion, their association with rCDI
decreased significantly (Table 4).
Discussion
We have identified eight discrete independent risk fac-
tors for recurrent CDI. Although some characteristics,
such as age, cannot be altered, several of them constitute
modifiable exposures. New gastric acid suppression and
concomitant antimicrobial exposures were associated
with increased hazards of developing recurrent CDI. Re-
ducing these exposures could potentially decrease the
risk of recurrent CDI. This may serve as yet another rea-
son for institutions to engage in aggressive antimicrobial
stewardship programs.
Prior investigations have reported advanced age, chronic
renal insufficiency, elevated white blood cell count, low
serum albumin, use of PPI and H2RB, as well as continued
use of systemic antimicrobials to be important risk factors
for rCDI [7,10-13,22]. Our results are in general agree-
ment with these prior data. Gastric acid suppressors have
garnered a particular interest with respect to their impact
on iCDI and rCDI incidence. Specific to recurrent disease,
a recent meta-analysis substantiated this concern, finding
a more-than doubling of the risk of rCDI in the setting of
these drugs [7]. At the same time, it is unclear whether
both PPIs and H2RBs are associated with the risk of rCDI,
or whether one is a more likely culprit than the other. For
example a meta-analysis by Kwok and colleagues impli-
cated PPIs but not H2RBs in a 2-fold rise of rCDI inci-
dence [23]. Similarly, Tleyjeh et al. in a meta-analysis of 33
studies focusing specifically on H2RB exposure reported a
smaller, albeit still significant, association between receiv-
ing H2RBs and development of CDI [24]. Both meta-
analyses suggested that gastric protection in conjunction
with antibiotic administration carries a higher risk of CDI
Table 2 Processes of care at the onset of and treatment for the initial CDI hospitalization
Patient characteristics
Patients who developed rCDI Patients who did not develop rCDI Hazard ratio
(n = 425) (n = 3775) 95% CI
Laboratory results iCDI onset
Low albumin 50 (12) 548 (15) 0.84 (0.63 – 1.13)
Low WBC 64 (15) 635 (17) 0.99 (0.82 – 1.20)
High WBC 247 (58) 2027 (54) 1.23 (1.01 – 1.49)
Low hemoglobin 218 (51) 1985 (53) 0.96 (0.79 – 1.16)
High creatinine 99 (23) 862 (23) 1.08 (0.86 – 1.35)
Relevant medications present at iCDI onset
Any antimicrobial 314 (74) 2729 (72) 1.10 (0.88 – 1.36)
Low risk antimicrobial(s)a 95 (22) 1058 (28) 0.76 (0.60 – 0.95)
High risk antimicrobial(s)b 174 (41) 1490 (40) 1.07 (0.88 – 1.29)
Fluoroquinolone 120 (28) 861 (23) 1.29 (1.05 – 1.60)
IV vancomycin 130 (31) 1321 (35) 0.86 (0.70 – 1.05)
Gastric acid suppressor, any 310 (73) 2850 (76) 0.91 (0.73 – 1.12)
New gastric acid suppressor 54 (13) 255 (7) 1.87 (1.41 – 2.49)
Relevant medications received following iCDI onset
Any antibiotic first dose after CDI 278 (65) 1622 (43) 2.47 (2.02 – 3.02)
Low risk antimicrobial(s) first dose after CDIa 141 (33) 710 (19) 2.09 (1.71 – 2.56)
High risk antimicrobial(s) first dose after CDIb 150 (35) 714 (19) 2.30 (1.89 – 2.81)
Fluoroquinolone first dose after CDI 124 (29) 703 (19) 1.69 (1.37 – 2.09)
IV vancomycin first dose after CDI 115 (27) 337 (12) 2.61 (2.11 – 3.23)
Initial CDI treatment
Metronidazole alone 323 (76) 2841 (75) Reference
Oral vancomycin alone 16 (4) 104 (3) 1.32(0.80 – 2.18)
Metronidazole and oral vancomycin 86 (20) 829 (22) 0.95 (0.75 – 1.20)
iCDI = initial episode of C. difficile infection, rCDI = recurrent C. difficile infection.
aLow risk antimicrobials included aminoglycosides, betalactamase inhibitors, carbepenems, daptomycin, doxycycline, linezolid, macrolides, penicillinase inhibitors,
rifampin, rifaximin, and tigecycline.
bHigh risk antimicrobials included all cephalosporins, clindamycin, and penicillins.
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development than exposure to PPIs or H2RBs alone
[23,24]. In our study, we examined gastric acid suppres-
sors as a single category because our prior work, including
preliminary analyses for this study (data not shown), has
consistently found no difference in the associations be-
tween these two classes of medications and CDI [17,18].
Whether gastric acid suppression is truly an independent
risk factor for CDI or a marker for patients at risk for CDI
remains unknown [6].
A large body of evidence also ties concomitant use of
non-CDI antimicrobials to an increased risk of a recur-
rence [7,17,18,25]. We found that high-risk antimicrobials
raise the risk for rCDI, particularly when administered after
the completion of iCDI treatment. We have also confirmed
previous findings that link exposure to such specific anti-
microbials as IV vancomycin and fluoroquinolones to the
risk for CDI incidence [17,18,26]. The BI/NAP1/027 strain
has been associated with fluoroquinolone exposures, and
may be more likely to cause rCDI than other strains of
C. difficile [27]. Consequently, it is possible that fluoro-
quinolone exposure is a marker for CDI specifically due to
this strain. For IV vancomycin, however, this association
may represent not a causal relationship, but rather a
marker for higher illness severity and, thus, confounding
by indication.
We were also able to demonstrate the importance of
timing of antimicrobial exposure after the end of CDI
treatment. When modeled as time dependent variables,
high-risk antimicrobials, fluoroquinolones, and IV
vancomycin were all associated with rCDI. When mod-
eled as time independent variables, the hazards of rCDI
associated with high-risk antimicrobials dropped from







(n = 425) (n = 3775) 95% CI
Discharged to a healthcare facility 130 (31) 1029 (27) 1.18 (0.96 – 1.45) 0.11
Inpatient readmission(s) before end of iCDI treatment 48 (11) 241 (6) 1.76 (1.30 – 2.37) <.001
Inpatient readmission(s) after end of iCDI treatment 126 (30) 857 (23) 1.31 (1.07 – 1.62) 0.01
iCDI = initial episode of C. difficile infection, rCDI = recurrent C. difficile infection.
Table 4 Cox proportional hazards multivariable model examining risk factors for recurrent CDI
Patient characteristics Antimicrobials after iCDI treatment modeled
as time dependent variables
Antimicrobials after iCDI treatment modeled
as time independent variables
Risk factor Hazard ratio 95% CI Hazard ratio 95% CI
At admission to the hospital
CDI case status
HO CDI Ref Ref
COHCFA CDI 1.80 1.41-2.29 1.78 1.39-2.27
CA CDI 1.30 0.95-1.80 1.25 0.91-1.72
Number of hospitalizations in previous 60 days
None Ref
1 1.25 0.97-1.61 1.27 0.99-1.64
>1 1.40 1.04-1.89 1.46 1.08-1.96
Age (per 1 year) 1.01 1.00-1.02 1.01 1.00-1.02
At the onset or during treatment of iCDI
Gastric acid suppression 1.36 1.00-1.85 1.40 1.03-1.90
Cumulative fluoroquinolone exposurea 1.24 1.09-1.41 1.42 1.25-1.61
Following completion of iCDI treatment
High risk antimicrobialb 2.95c 2.25-3.86 1.86 1.42-2.42
Fluoroquinolone 1.56c 1.63-2.08 0.86 0.64-1.15
IV vancomycin 1.45c 1.09-1.92 1.05 0.80-1.39
iCDI = initial episode of C. difficile infection.
aCumulative fluoroquinolone exposure was modeled as a three node spline.
bHigh risk antimicrobials included all cephalosporins, clindamycin, and penicillins.
cExposure at any time t.
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2.95 (2.25-3.86) to 1.86 (1.42-2.42), and fluoroquinolones
and IV vancomycin were no longer associated with
rCDI. Intuitively, this makes sense. An antimicrobial
should not increase the risk of rCDI after CDI treatment
has ended until the patient is exposed to the antimicro-
bial. Not modeling antimicrobials as time dependent var-
iables after CDI treatment has ended dilutes the
association with rCDI, since the days not on these drugs
are included in the model.
A direct relationship between CO-HCFA status and
iCDI and rCDI development is a newer finding [15].
Namely, the CO-HCFA designation of the iCDI episode
is associated with at least a 25% and as much as a 2-fold
increase in the risk of rCDI. A likely mechanism relates
to the fact that CO-HCFA defines a population of pa-
tients who is likely sicker as evident by recent hospitali-
zations, and more likely to be exposed to antimicrobials.
However, CO-HCFA CDI remained an independent risk
factor when controlling for recent hospitalizations.
It is worth noting that the recurrence rate we observed
in the current study is at the lower end of what has been
reported previously. For example, a recent meta-analysis
by Garey et al. examined the literature on risk factors for
rCDI [7]. In the 12 studies meeting the inclusion criteria,
the rates of recurrence ranged from 13% to 50%. More
current data from randomized controlled trials suggest
that CDI is likely to recur in approximately 25% of the
patients treated for iCDI with vancomycin [8,9]. A po-
tential explanation for the lower rCDI rate in our study
compared to others is how cases of CDI were identified.
Most stools submitted for C. difficile testing at the BJH
microbiology laboratory come from inpatients and the
emergency room. A minority of specimens come from
outpatients or affiliated skilled nursing facilities. It is
likely that milder cases of rCDI were missed because the
patient did not require care in an emergency room or
need to be admitted. Therefore, the rCDI in this study
may consist of more clinically important episodes, oc-
curring in sicker patients, many of whom required an
admission or evaluation in the emergency department.
It is possible that patients who resided outside the St.
Louis metropolitan area would not be likely to return to
BJH for testing for a recurrence. To examine the impact
of this potential loss to follow up, we performed a sensi-
tivity analysis of rCDI risk factors by excluding all pa-
tients who resided beyond the greater St. Louis postal
code. After excluding the 1230 (31.1%) patients with
iCDI who met this criterion, the rCDI risk factors and
their hazard ratios did not change appreciably (data not
shown). This suggested that our results were not biased
by including these patients.
Conversely, rCDI in randomized trials may be subject
to a detection bias. Patients in trials are prospectively
monitored for recurrent diarrhea and instructed to seek
testing if it occurs. Even if the patient’s symptoms are
not from CDI, the person may test positive for CDI as
many patients continue to shed C. difficile in stool after
cessation of CDI treatment [28].
Our study has some limitations. As a retrospective ob-
servational study it is prone to several forms of bias,
most notably a selection bias. To mitigate this, we en-
rolled all consecutive patients meeting our enrollment
criteria. To avoid misclassification of the main outcome
variable, we applied a stringent case definition to CDI,
which included a positive toxin assay. Although con-
founding is an issue with observational data, we adjusted
for all the available relevant potential confounders in the
regression model. However, the possibility of residual
confounding remains. The biggest limitation, however, is
its generalizability, since the data reflected patients and
treatment patterns at an urban academic medical center
with a large referral base, and may not have mirrored
those of institutions with different characteristics or pa-
tients with iCDI diagnosed and managed completely in
the outpatient setting. Additionally, many of the patients
who resided outside the St. Louis metropolitan area may
not have had their specimens retested at the BJH labora-
tory. After excluding these patients from the analysis as
part of a sensitivity analysis, neither the rCDI hazard ra-
tios nor the rCDI risk factors were majorly impacted in
the overall cohort.
Conclusion
In summary, we have demonstrated that a number of
modifiable factors exist whose presence raises the risk
for developing rCDI. Avoiding such exposures as non-
CDI antimicrobial treatment and gastric acid suppres-
sors may go a long way toward attenuating the burden
of rCDI. On the other hand recognizing CO-HCFA and
advanced age as predispositions to rCDI should serve
patients and clinicians well by highlighting the import-
ance of targeting these populations for more aggressive
prevention efforts.
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